Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Codiak Biosciences Inc's Business Segments
Codiak Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Codiak Biosciences Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Grant94.6%
- Collaboration5.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 0 | 94.6% |
| Collaboration | $ 0 | 5.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Codiak Biosciences Inc
Codiak Biosciences Inc is a biotechnology company focused on developing exosome-based therapeutics for the treatment of various diseases. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Codiak's core technology revolves around exosomes, which are small extracellular vesicles that play a crucial role in intercellular communication. These vesicles are secreted by cells and contain proteins, nucleic acids, and other molecules that can transfer information between cells. Codiak harnesses the power of exosomes to develop novel therapies that can potentially address multiple disease indications.
The company's platform technology enables the identification, engineering, and manufacturing of exosomes with precise properties, allowing for the targeted delivery of therapeutic cargo to specific tissues or cells. Codiak's proprietary manufacturing processes ensure the reproducible production of exosomes with consistent quality, purity, and scalability.
Codiak's therapeutic pipeline includes both internal programs and collaborations with pharmaceutical partners. The company is primarily focused on developing exosome therapeutics for cancer, neurology, and musculoskeletal disorders. They are working on targeted drug delivery strategies to enhance the efficacy and safety of therapeutic payloads.
In the field of oncology, Codiak is developing exosome-based therapies to address various aspects of cancer, such as tumor growth, metastasis, and immunosuppression. They aim to develop therapies that can modulate the tumor microenvironment, enhance immune responses, and deliver anticancer agents directly to tumor cells.
In neurology, Codiak is exploring the potential of exosome therapeutics for the treatment of neurodegenerative diseases like Parkinson's and Alzheimer's. By harnessing the ability of exosomes to transfer functional proteins and nucleic acids, the company aims to develop therapies that can promote neural regeneration, provide neuroprotection, and alleviate disease symptoms.
Codiak's musculoskeletal program focuses on developing exosome-based therapies for conditions like osteoarthritis and osteoporosis. By targeting specific cell populations in the joints and bones, their therapies aim to promote tissue repair, reduce inflammation, and enhance bone density.
Overall, Codiak Biosciences Inc is at the forefront of developing exosome-based therapeutics with the potential to revolutionize disease treatment. Through their innovative platform technology, they aim to unlock the full potential of exosomes to deliver safe and effective therapies for a wide range of diseases.
Codiak's core technology revolves around exosomes, which are small extracellular vesicles that play a crucial role in intercellular communication. These vesicles are secreted by cells and contain proteins, nucleic acids, and other molecules that can transfer information between cells. Codiak harnesses the power of exosomes to develop novel therapies that can potentially address multiple disease indications.
The company's platform technology enables the identification, engineering, and manufacturing of exosomes with precise properties, allowing for the targeted delivery of therapeutic cargo to specific tissues or cells. Codiak's proprietary manufacturing processes ensure the reproducible production of exosomes with consistent quality, purity, and scalability.
Codiak's therapeutic pipeline includes both internal programs and collaborations with pharmaceutical partners. The company is primarily focused on developing exosome therapeutics for cancer, neurology, and musculoskeletal disorders. They are working on targeted drug delivery strategies to enhance the efficacy and safety of therapeutic payloads.
In the field of oncology, Codiak is developing exosome-based therapies to address various aspects of cancer, such as tumor growth, metastasis, and immunosuppression. They aim to develop therapies that can modulate the tumor microenvironment, enhance immune responses, and deliver anticancer agents directly to tumor cells.
In neurology, Codiak is exploring the potential of exosome therapeutics for the treatment of neurodegenerative diseases like Parkinson's and Alzheimer's. By harnessing the ability of exosomes to transfer functional proteins and nucleic acids, the company aims to develop therapies that can promote neural regeneration, provide neuroprotection, and alleviate disease symptoms.
Codiak's musculoskeletal program focuses on developing exosome-based therapies for conditions like osteoarthritis and osteoporosis. By targeting specific cell populations in the joints and bones, their therapies aim to promote tissue repair, reduce inflammation, and enhance bone density.
Overall, Codiak Biosciences Inc is at the forefront of developing exosome-based therapeutics with the potential to revolutionize disease treatment. Through their innovative platform technology, they aim to unlock the full potential of exosomes to deliver safe and effective therapies for a wide range of diseases.
Codiak Biosciences Inc. is a pioneering biotechnology company specializing in the development and commercialization of exosomes as next-generation therapeutic products. Exosomes are nano-sized extracellular vesicles that are naturally released by all cell types and are integral to intercellular communication, playing crucial roles in various physiological and pathological processes. Codiaks innovative approach centers on harnessing and engineering exosomes to create targeted therapies for a wide range of diseases, thus offering new hope for patients suffering from conditions that are currently difficult to treat.
Segments
Codiak Biosciences operates primarily within the biotechnology segment focused on exosome therapeutics. Within this sector, the company’s activities can be categorized into several key areas:
1. Research and Development (R&D): This is the core of Codiak’s business, where extensive research is conducted to explore the potential of engineered exosomes. The R&D segment includes discovering new therapeutic targets, designing exosome-based drugs, and conducting preclinical and clinical studies to evaluate their safety and efficacy.
2. Therapeutic Areas: Codiak’s efforts span various therapeutic areas, including:
- Oncology: Targeting cancer through immunotherapy, leveraging their engineered exosomes to enhance anti-tumor immunity.
- Neurology: Developing therapies for neurodegenerative diseases, utilizing exosomes both as drug delivery vehicles and as therapeutic agents.
- Immunology: Focusing on autoimmune diseases and improving immune responses through tailored exosomal therapies.
- Infectious Diseases: Exploring the potential of exosomes in combating infectious agents and modulating immune responses.
Products
Codiak Biosciences boasts an exciting array of engineered exosome products, each tailored to address specific medical needs and therapeutic indications. Key products in development include:
1. exoSTING: This is Codiaks flagship product, an engineered exosome designed to activate the innate immune system. By enhancing the bodys natural anti-tumor responses, exoSTING holds promise in the fight against various cancers.
2. Therapeutic Candidates for Neurological Disorders: Codiak is actively developing exosome-based treatments aimed at diseases such as Alzheimer’s, Parkinson’s, and other neurodegenerative conditions. These products leverage exosomes ability to cross the blood-brain barrier and deliver therapeutic agents directly to affected cells.
3. Exosome-Based Therapies for Autoimmune Disorders: The company is working on innovative approaches that utilize engineered exosomes to restore immune balance in conditions like lupus and rheumatoid arthritis.
4. Infectious Disease Applications: Codiak is investigating exosome therapies aimed at treating viral infections and other infectious diseases, potentially reformulating conventional therapeutic strategies.
Each of these products is at varying stages of development, encompassing preclinical research to advanced clinical trials.
Services
Beyond its therapeutic product pipeline, Codiak Biosciences offers a suite of services that cater to the growing field of exosome research:
1. Exosome Isolation and Characterization: Codiak utilizes proprietary technologies for the isolation and purification of exosomes from various cell types, ensuring high-quality starting materials for research and therapeutic applications.
2. Exosome Engineering: The company provides expertise in manipulating exosomes to enhance their efficacy as drug delivery systems. This involves loading therapeutic cargo, modifying surface proteins to improve targeting, and customizing exosome characteristics to meet specific research or clinical needs.
3. Collaborative Partnerships: Codiak actively seeks strategic collaborations with other biotech and pharmaceutical companies. By partnering with external organizations, Codiak can leverage its exosome platform for joint research initiatives and therapeutic development efforts.
4. Consultative Services: As experts in the field, Codiak may offer consultative services to other organizations looking to explore or implement exosome-based technologies in their own R&D processes.
Conclusion
In summary, Codiak Biosciences Inc. stands at the frontier of biotechnology with its focus on exosome therapeutics. The companys commitment to engineering exosomes for targeted delivery of therapeutic agents highlights its innovative approach to addressing significant medical challenges. Through a comprehensive pipeline of products and a robust set of services, Codiak Biosciences is positioned as a leader in the burgeoning field of exosome-based medicine, offering solutions across a spectrum of therapeutic areas.
Segments
Codiak Biosciences operates primarily within the biotechnology segment focused on exosome therapeutics. Within this sector, the company’s activities can be categorized into several key areas:
1. Research and Development (R&D): This is the core of Codiak’s business, where extensive research is conducted to explore the potential of engineered exosomes. The R&D segment includes discovering new therapeutic targets, designing exosome-based drugs, and conducting preclinical and clinical studies to evaluate their safety and efficacy.
2. Therapeutic Areas: Codiak’s efforts span various therapeutic areas, including:
- Oncology: Targeting cancer through immunotherapy, leveraging their engineered exosomes to enhance anti-tumor immunity.
- Neurology: Developing therapies for neurodegenerative diseases, utilizing exosomes both as drug delivery vehicles and as therapeutic agents.
- Immunology: Focusing on autoimmune diseases and improving immune responses through tailored exosomal therapies.
- Infectious Diseases: Exploring the potential of exosomes in combating infectious agents and modulating immune responses.
Products
Codiak Biosciences boasts an exciting array of engineered exosome products, each tailored to address specific medical needs and therapeutic indications. Key products in development include:
1. exoSTING: This is Codiaks flagship product, an engineered exosome designed to activate the innate immune system. By enhancing the bodys natural anti-tumor responses, exoSTING holds promise in the fight against various cancers.
2. Therapeutic Candidates for Neurological Disorders: Codiak is actively developing exosome-based treatments aimed at diseases such as Alzheimer’s, Parkinson’s, and other neurodegenerative conditions. These products leverage exosomes ability to cross the blood-brain barrier and deliver therapeutic agents directly to affected cells.
3. Exosome-Based Therapies for Autoimmune Disorders: The company is working on innovative approaches that utilize engineered exosomes to restore immune balance in conditions like lupus and rheumatoid arthritis.
4. Infectious Disease Applications: Codiak is investigating exosome therapies aimed at treating viral infections and other infectious diseases, potentially reformulating conventional therapeutic strategies.
Each of these products is at varying stages of development, encompassing preclinical research to advanced clinical trials.
Services
Beyond its therapeutic product pipeline, Codiak Biosciences offers a suite of services that cater to the growing field of exosome research:
1. Exosome Isolation and Characterization: Codiak utilizes proprietary technologies for the isolation and purification of exosomes from various cell types, ensuring high-quality starting materials for research and therapeutic applications.
2. Exosome Engineering: The company provides expertise in manipulating exosomes to enhance their efficacy as drug delivery systems. This involves loading therapeutic cargo, modifying surface proteins to improve targeting, and customizing exosome characteristics to meet specific research or clinical needs.
3. Collaborative Partnerships: Codiak actively seeks strategic collaborations with other biotech and pharmaceutical companies. By partnering with external organizations, Codiak can leverage its exosome platform for joint research initiatives and therapeutic development efforts.
4. Consultative Services: As experts in the field, Codiak may offer consultative services to other organizations looking to explore or implement exosome-based technologies in their own R&D processes.
Conclusion
In summary, Codiak Biosciences Inc. stands at the frontier of biotechnology with its focus on exosome therapeutics. The companys commitment to engineering exosomes for targeted delivery of therapeutic agents highlights its innovative approach to addressing significant medical challenges. Through a comprehensive pipeline of products and a robust set of services, Codiak Biosciences is positioned as a leader in the burgeoning field of exosome-based medicine, offering solutions across a spectrum of therapeutic areas.